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INTRODUCTION.
Herpes simplex virus type 1 (HSV-1) is a double-stranded DNA virus with very high infective rates in humans [1] . Although the primary site of HSV-1 infection is the orolabial mucosa, it can also cause disease in all of the major ocular tissues, including the conjunctiva, cornea, uveal tract, and retina. After this primary infection, the HSV-1 virus is transported to the trigeminal ganglion where it establishes a lifelong latent infection that can be reactivated by several stimuli [2] . When reactivation occurs, HSV-1 is transported back to the primary site of infection where it causes recurrent ulcerations. The potent immune response to the viral proteins triggers the ingrowth of blood vessels, infiltration of leukocytes, and damage to the corneal stroma and endothelium that combine to promote corneal opacity and edema, leading to an immunopathology known as herpetic stromal keratitis (HSK) that may result in blindness and, in rare cases, brain infections [3] .
Current HSK treatment involves the use of topical corticosteroids to reduce inflammation. But the immunosuppressive effect associated with corticosteroids usually induces viral reactivation that must eventually be mitigated with an antiviral drug such as acyclovir. A common outcome of this treatment is the emergence of acyclovirresistant viral strains, essentially due to long-term antiviral therapy in combination with an impaired host response, which enables the less virulent viruses to continue to replicate [4] . Thus, the development of new antiherpetic compounds for HSK treatment is a crucial challenge.
We previously showed that synthetic steroids 1 and 2 ( Figure 1 ) inhibit HSV-1 multiplication and viral spreading in a human conjunctival cell line (IOBA-NHC), with no cytotoxicity. Furthermore, these compounds significantly decrease the incidence of HSK in infected mice, even when administered during the inflammatory phase of the disease [5] . This fact led us to consider the possibility that these steroids might combine antiviral activity with immunomodulating properties. Indeed, in macrophages stimulated with lipopolysaccharide (LPS) and treated with compound 1, the production of inflammatory cytokines such as TNF-α and IL-6 is significantly inhibited, comparable to the effects of dexamethasone (DEX), a widely used corticosteroid [6] .
Compounds 1 and 2 belong to steroids of stigmastane series, which include sterols such as sitosterol and stigmasterol (commonly found in plants but absent in animals)..
However, these compounds share some moieties with corticosteroids (a 3-keto-Δ 4 system in ring A and an hydroxylated side chain), which led us to hypothesize that their inmmunomodulating properties might be associated with a corticoid-like activity.
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On the other hand, since the first report of fluorination of the glucocorticoid hormone cortisol in 1954 [7] it is known that the introduction of a 6α-fluorine into a glucocorticoid has a large and increasing effect on anti-inflammatory activity. Several topically active products containing this functionality, for example paramethasone, have been developed and are in clinical use [8] .
Taking into account these precedents, and with the aim to study the effect of fluorination on the in vitro immunomodulating activity of compounds 1 and 2, we decided to synthesize new analogs bearing a fluorine atom at C-6 (compounds 3a, 3b, 4a and 4b, Figure 1) . Furthermore, the anti HSV-1 activity of the compounds was assessed in a cell line relevant to ocular infections.
MATERIALS AND METHODS.
Synthesis of the compounds.
All solvents and reagents were purchased from Sigma-Aldrich Chemical Co. 
Cytotoxicity assay.
To evaluate the cytotoxicity of the compounds, cell viability was determined as previously reported [24] . Compounds were dissolved in dimethylsulfoxide (DMSO) and diluted with culture medium for testing.
The maximum concentration of DMSO tested was between 0.1% and 1% v/v and exhibited no cytotoxicity under the experimental conditions. The absorbance of each well was measured on a Eurogenetics MPR-A 4i microplate reader using a test wavelength of 570 nm and a reference wavelength of 630 nm. Results are expressed as percent absorbance of treated cells with respect to untreated cells. The Cytotoxic Concentration 50% (CC50) was defined as the concentration of compound that caused a 50% reduction in cell viability.
Antiviral activity.
To The Effective Concentration 50% (EC 50 ) was defined as the concentration of compound that caused a 50% reduction in virus multiplication. Selectivity indices (SI) for each compound were obtained from CC 50 / EC 50 ratios.
Determination of cytokine profiles.
To determine cytokine responses, J774A.1 cells grown in 24-well plates were incubated at 37 ºC in the presence or absence of different concentrations of the Tolllike receptors 2, 4 and 9 (TLR2, TLR4 and TLR9) ligands, in duplicate. After 8 h, supernatants were harvested and murine TNF-α and IL-6 were quantified by commercial ELISA sets (BD OptEIATM, Becton Dickinson, USA) according to the manufacturer's instructions.
Western blot analysis.
Whole extracts of cells grown in 24-well plates for 24 h were run in a 10 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred onto polyvinylidene fluoride membranes for 60 min at 75 mA. Membranes were blocked in PBS containing 5 % nonfat milk overnight and then incubated with diluted primary antibodies overnight at 4ºC. After washing, membranes were incubated with diluted peroxidase-conjugated antibodies for 1.5 h at 37ºC. The immunoreactive bands were visualized using an enhanced chemiluminescence system (ECL, PerkinElmer).
Transfections.
Transfection assays with Lipofectamine 2000 reagent (Invitrogen) were performed according to the manufacturer's instructions. The NF-κB-LUC reporter vector and RSV-β-gal plasmid were kindly provided by Dr. Susana Silberstein (University of Buenos Aires). RSV-β-gal, which codes for the bacterial β-galactosidase gene under the control of the viral RSV promoter, was used as second control reporter plasmid.
Preparation of thymus cytosol.
Thymus cytosol was prepared following a previously described protocol [25] . Male supplemented with a cocktail of protease inhibitors) and centrifuged at 67,000 g for 30 min at 0°C. The supernatant hereafter referred to as cytosol was used immediately.
Preparation of fibroblast cytosol.
To prepare fibroblast cytosol, HEK293T cells were grown to ~ 50% confluence, at which point the culture medium was replaced by Opti-MEM. After 1 h, cells were transfected with either 2.5 µg of the plasmid pSV2rec-GR, which encodes for mouse GR, or with pCINeo-flagMR, which encodes for human MR, using a liposome (Transfast, Promega) vehicle, The cells were collected by trypsinization 48 h later, washed with PBS and homogenized in HEM buffer, as described for the preparation of thymus cytosol.
Displacement assays.
Cytosols were incubated with 20 nM [ 
Immunofluorescence.
HEK293T cells grown on coverslips pretreated with polylysine to promote cell adhesion were transfected with a chimeric GR associated with Green Fluorescent Protein (GFP), as described in the previous section. After 24 h of growth in a medium containing serum adsorbed with carbon/dextran (and thus steroid-free), cells were stimulated with 100 nM DEX, 1 µM of the compound of interest, or both compounds simultaneously.
After 30 min of incubation, the coverslips were washed with PBS, fixed with 3% pformaldehyde, permeabilized with methanol at -20°C and the subcellular localization of GFP-GR observed with an epifluorescence microscope.
Transcriptional activity assays.
HEK293T cells were transfected with 1 µg pCINeo-flag-MR or GFP-GR following a previously published protocol [26] . Concisely, 0.1 µg mouse mammary tumor virus-luciferase (MMTV-Luc) and 50 ng of RSV-β-galactosidase were cotransfected with one of the receptors following the calcium phosphate precipitation standard method. After 36 h incubation in a medium containing charcoal-stripped serum, cells were stimulated with steroid for 12 h. Luciferase and β-galactosidase activities were measured and luciferase activity was normalized to β-galactosidase expression.
Statistical analysis.
One-way ANOVA analysis for paired samples was used to determine the significance of the differences between mean values in all control and tested samples using GraphPad Prism software. The analysis was complemented with a Tukey post-test to compare mean values.
RESULTS.
Synthesis of the fluorinated analogs.
The synthesis of the new fluorinated analogs is depicted in Scheme 1. Fluorination at C-6 was achieved via a well-established procedure that signifies the electrophilic fluorination of the corresponding steroidal 3,5-dienol acetate. Thus, the dienol acetate 6, which was obtained from commercial stigmasterol in two steps, was subjected to
bistetrafluoroborate (Selectfluor). This fluorinating agent was chosen because it is the most suitable reagent for the required fluorination [9] .
The mixture of the 6α-and 6β-fluoroenones 7a and 7b, which was obtained in a 3:1 ratio, was separated by column chromatography. The configuration assignment at C-6 was established from the coupling patterns observed in the yield. Similarly, application of the dihydroxylation -dehydrogenation sequence on the 6β-fluoro isomer 7b yielded compounds 3b and 4b.
3.2
Biological activity of the compounds.
3.2.1 Effect on cytokine production in stimulated macrophages.
It is well known that macrophages play a role in non-specific defense against viral infections and are a source of inflammatory mediators, such as TNF-α and IL-6.
Specifically, in the HSK murine model, macrophages participate in the inflammatory response in the eye and are involved in the development of the immunopathology.
We previously found that compound 1 diminishes TNF-α and IL-6 secretion in a dosedependent manner when murine macrophages are stimulated with LPS, a TLR4
agonist [6] . TLR-4 plays an important role in the innate immune system, and is proposed to be one of the TLRs involved in the recognition events following HSV-1 infection. Thus, we decided to extend this study to compound 2 and their fluorinated counterparts 3a, 3b, 4a and 4b. Compound 1 was also included in the assays for comparative purpose.
First, we determined the cytotoxicity of the compounds on J774A.1 cells. All of them exhibited CC50 values higher than 100 µM ( Figure 2A ).
We observed a basal production of 0.6 ± 0.1 ng/ml of TNF-α and 0.1 ± 0.1 ng/ml of IL-6 in the absence of LPS in J774A.1 cells. When macrophages were stimulated with 100 ng/ml of LPS, the secretion of TNF-α and IL-6 increased, 8 h after stimulation, to 152.3 ± 15.1 ng/ml and 18.8 ± 3.3 pg/ml, respectively ( Figure 2B and C). When this experiment was performed in the presence of the steroidal compounds, a doseresponse inhibition was observed ( Figure 2B and C) . In addition, none of the compounds were able to induce an increase in cytokine levels alone (shown in Supplementary data).
On the other hand, because TLR-2 and 9 receptors are also known to be involved both in the early recognition of HSV and cytokine secretion in the response to HSV infection
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[15-17], the effect of the compounds on the production of TNF-α and IL-6 when macrophages were stimulated with the appropriate ligands was determined. Figure 3 shows that when J774A.1 cells were treated with 100 ng/ml of a synthetic diacylated lipoprotein (Pam2CSK4, a TLR-2 agonist), or 5 µg/ml of ODN2395 (a TLR9 agonist), the production of TNF-α increased significantly ( Figure 3A and C, respectively). When these experiments were preformed in the presence of 40 µM of the compounds, the cells activated with either stimulus reduced production of this cytokine.
Stimulation with Pam2CSK4 induced an increase in IL-6 production ( Figure 3B ), while no secretion of IL-6 was observed in J774A.1 cells stimulated with ODN2395. All of the compounds tested were able to reduce IL-6 production. Figure 3 depicts the results for compounds 1, 3a and 4a as representative examples of this behavior. Interestingly, although all of the compounds modulated both the TNF-α and the IL-6 production induced by the TLR ligands in a similar fashion to DEX [18] , fluorination at C-6 does not seem, contrary to our expectations, to enhance the immunomodulatory effect.
Glucocorticoid activity of the synthetic steroids.
In order to confirm that the observed immunomodulatory effects were associated to glucocorticoid-like activity, we decided to directly evaluate the binding of the compounds to the glucocorticoid receptor (GR). Thus, we performed a displacement assay in which either native GR from murine thymus or mouse GR overexpressed in the human embryonic kidney cell line 293T (HEK293T) were used. As a displacement control we used unlabeled dexamethasone (DEX) or corticosterone (CORT).
To analyze possible cross reactions with the mineralocorticoid receptor (MR), which shares a very high homology with GR, displacement assays of the compounds were carried out with aldosterone (ALDO) as a control.
Figures 4A and B show the competition curves for GR extracts in thymus and HEK cells transfected with GR, respectively. As expected, both unlabeled CORT and DEX competed effectively with the tracer for GR. However, compound 1 did not show affinity for this receptor or cross reactivity to MR ( Figure 4C ). Furthermore, none of the other compounds (2, 3a, 3b, 4a or 4b) showed affinity for GR at a 100-fold excess of nonradioactive hormone (data not shown).
It is well known that steroid receptors are not statically confined to a given cell compartment, but move constantly between the cytoplasm and the nucleus. The
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None of the compounds induced GFP-GR nuclear localization per se, corroborating that they were not able to bind GR ( Figure 5 ). In the presence of DEX, immunofluorescence images showed that GFP-GR localizes, as expected, in the nucleus.
To Although 0.1 µM DEX led to 100% relative luciferase activity, none of the compounds assessed was able to activate the transcription via GR at any of the concentrations tested ( Figure 6A ). When transcriptional activity of MR was assayed, a similar result was obtained, since none of the compounds were able to induce the reporter gene via MR, and the positive control ALDO was ( Figure 6B ).
In conclusion, none of the synthetic stigmastanes were able to bind the glucocorticoid or mineralocorticoid receptors.
Activation of signaling pathways
Since the stigmastanes modulated both the TNF-α and the IL-6 production induced by TLR ligands, but by a different mechanism than glucocorticoids, we investigated whether NF-κB, Akt and ERK intracellular signaling pathways, which are involved in the regulation of cytokine production, were affected. As compound 1 was extensively studied in our previous work, it was chosen to perform the following experiments NF-κB is a major signaling pathway activated by HSV-1 infection [19] . A series of phosphorylation / recruitment / activation events, such as degradation of IκB, lead to NF-κB nuclear translocation and transcription of inflammatory cytokine genes [20] . In
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Compound 1 did not degrade IκB in non-stimulated cells (Fig. 7A) . TLR2, TLR4 and TLR9 stimulation caused IκB degradation, and the addition of 1 did not prevent IκB disappearance (Fig. 7A) . Consequently, we hypothesized that compound 1 might inhibit a downstream step in IκB degradation and NF-κB translocation. Therefore, we used a NF-κB-LUC reporter plasmid to explore whether NF-κB-induced transcription was affected.
With this end, J774A.1 cells were transfected with the NF-κB-LUC reporter vector and β-galactosidase control plasmid and, 24 h later, were treated with 1 (40 µM). After 8 h, luciferase activity was measured in cell extracts and each value was normalized to β-galactosidase activity. All of the TLRs agonists caused significant NF-κB activation, but this activation was not hampered by compound 1 regardless of the TLR used (Fig. 7B) .
Next, we determined if compound 1 could modulate ERK and/or Akt phosphorylation in cells stimulated with the TLR agonists. J774A.1 cells stimulated with Pam2CSK4 (100 ng/ml), LPS (100 ng/ml) and ODN2395 (5 µg/ml) were treated with compound 1 (at 40 µM) for 1 h. Cells were then processed in a Western blot using antibodies against pERK, ERK, pAkt and Akt.
Compound 1 was not able to activate either the ERK or the Akt pathways by itself, whereas the three TLR agonists induced, as expected, phosphorylation of ERK and Akt, ( Figure 7C ). Interestingly, compound 1 completely blocked both the ERK and the Akt phosphorylation triggered by the TLR agonists in macrophages (Fig 7C) . Hence, the modulation of TNF-α and IL-6 secretion observed in compound 1 might be associated with the inhibition of the ERK and Akt signaling pathways.
Antiviral activity
The ocular surface consists of the corneal and conjunctival epithelia, which are closely Firstly, the cytotoxic concentration 50% (CC 50 ) of each compound was determined to be higher than 200 µM (Fig 8A and B) Figures 8C and D) . Interestingly, the most potent compound was 4b, a surprising result considering that 2, its nonfluorinated parent compound, showed no significant antiviral activity.
DISCUSSION
In previous studies we described a family of synthetic stigmastanes derived from stigmasterol, a major plant sterol, that share not only a wide spectrum of antiviral activity [13, 21, 22] , but also anti-inflammatory properties [23, 24] . The fact that the immunomodulation by these compounds resembled in part immunomodulation by glucocorticoids, led us to hypothesize that these two families of steroids might share a common mechanism of action. Nevertheless, the results shown in this work ruled out this possibility. We have demonstrated that these stigmastanes are not agonists of the glucocorticoid receptor; furthermore, they are not able to inhibit the NF-κB pathway when macrophages are stimulated with several TLRs ligands, as glucocorticoids do.
Moreover, our results show that their immnunomodulating activity might be associated with the inhibition of the ERK and Akt signaling pathways.
On the other hand, although the antiviral activity of natural and synthetic steroids have been known for some decades [13, [25] [26] [27] , the understanding of their mechanism of action has remained elusive [28] . In recent years, however, a major breakthrough showed that endogenous oxysterols, especially 25-hydroxycholesterol (25HC), play an important role in both innate and adaptive immunity during viral infection and demonstrate antiviral activity, establishing a link between these two biological activities [29] [30] [31] [32] . M A N U S C R I P T
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These findings may shed light on our results: it is possible that the stigmastanes exert their effects through a mechanism related to that of oxysterols. Firstly, there is a high structural similarity between the oxysterols and the stigmastanes described here.
Furthermore, the hydroxylated side chain present on these stigmastanes is essential, as previously mentioned, for the antiviral and anti-inflammatory activity; interestingly, cholesterol is converted into 25HC by a Ch25h-mediated hydroxylation of the side chain. On the other hand, the stigmastanes inhibit both ERK and Akt signaling pathways: the activation of the ERK pathway is known to trigger the activation of the AP-1 family transcription factors [33] , which is modulated by 25HC [32] Effect of the compound on IκBα degradation and NF-κB activation. J774A.1 cells were stimulated with TLR4 ligand (100 ng/ml), TLR2 ligand (100 ng/ml) and TLR9 ligand (5 mg/ml) and treated or not with compound 1 (40µM). After 60 min, macrophages were lysed and subjected to SDS-PAGE, followed by immunoblotting with antibodies against IκBα and actin. (B) J774A.1 cells were transfected with 0.5 µg of NF-B-LUC reporter vector and 0.5 µg of β-galactosidase control plasmid. After 24 h, J774A.1 cells were stimulated with TLR2, TLR4 (100 ng/ml) and TLR9 (5 µg/ml) ligands for 8 h, in the presence or not of compound 1 (40 µM). Luciferase activity was measured in cell extracts and each value was normalized to β-galactosidase activity in relative luciferase units (RLU). Data are expressed as the mean ± S.D. of three separate experiments. * indicates significant differences with respect to cell control (CC) (p < 0.05). (C) Effect of compound 1 on ERK and Akt activation. J774A.1 cells were stimulated with TLR2, TLR 4 or TLR 9 ligands for 60 min and treated or not with 40 μM of compound 1.
Macrophages were lysed and subjected to SDS-PAGE, followed by immunoblotting with antibodies against pERK, ERK, pAkt and Akt. 
